2022 NRDL Pricing Implications and Access Outcomes

Home / Intelligence / Webinars / 2022 NRDL Pricing Implications and Access Outcomes

Available On Demand

What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access?

The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies.

In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an in-depth analysis of the 2022 NRDL and key trends from previous NRDL negotiations. We will discuss the pricing implications and evidence strategies needed to secure public funding in China, along with how to navigate key NRDL strategies.

Key Webinar Topics:

  • Introduction to NRDL and China access landscape overview
  • Key updates in 2022 NRDL
  • Case studies of oncology, rare disease and chronic disease drugs


Complete the form below to view the on-demand webinar.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.

This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.

Related Intelligence


2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility

May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET

An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]

 Sign Up Now


Rise with the waves: Italy – AIFA restructuring and budget reforms – Stepping into a new (uncertain) future?

Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the appointment of a new acting chairman, highlighting the need for a stable and collaborative […]

 Read More


Annual State of Global Market Access Webinar

Available On Demand

Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]

 Watch Now